| 2011 |
Dr. Janni Papakrivos |
Regulatory Strategy for the Development of Known Drugs in New Therapeutic Areas *** |
|
|
| 2011 |
Christina Pfaffendorf |
Development of Generic Oral Human Medicinal Products Suitable for the Registration in the EU as well as the USA – Different Requirements, Feasibility, Time and Cost *** |
|
|
| 2011 |
Dr. Petra Regenhard |
Regulatory Requirements in the European Union for Avian Vaccines: Impact of the "Guideline on Data Requirements for Immunological Veterinary Medicinal Products intended for Minor Use or Minor Species/Limited Markets" on Clinical Research |
|
|
| 2011 |
José Rodríguez Sánchez |
Switzerland: Article 13 Act on Therapeutic Products - A Review *** |
|
|
| 2011 |
Christian Schlutius |
A step beyond module 3 of orodispersible films |
|
|
| 2011 |
Dr. Saskia Siewert |
Implementation of Quality by Design in the Pharmaceutical Development of semisolid topical drug products *** |
|
|
| 2011 |
Dr. Liane Söllner |
The need for juvenile animal studies - a critical review *** |
|
|
| 2011 |
Sebastian Strobl |
Counterfeit drugs in industrialized and developing countries - A comparison *** |
|
|
| 2011 |
Dr. Verena Tautorat |
The end of an era: Implementing Variation Directive 2009/53/EC into German Drug Law *** |
|
|
| 2011 |
Dr. Franz Thannberger |
A Step beyond Module 3 of "passive" Transdermal Therapeutic Systems *** |
|
|
| 2011 |
Anja Then-Kania |
Postapproval CMC Changes in the United States with a Focus on Biopharmaceuticals - Current Status and an Outlook in the Pharmaceutical Development *** |
|
|
| 2011 |
Kristina Tripp |
Case Study: Impact of a new German law ("AMNOG") to restructure the pharmaceutical market on a Generic Company |
|
|
| 2011 |
Dr. Alexander Vuia |
First revision of the "Guideline on the Investigation of bioequivalence": BCS-based Biowaiver - opportunities and limitations |
|
|
| 2011 |
Dr. Bettina Walter-Lorenzen |
Improvement of the workflow, quality and effective management of product information texts using a new database |
|
|
| 2011 |
Dr. Günter Waxenecker |
The "Risk Based Approach" - an important tool for managing all the duties in Drug Regulatory Affairs *** |
|
|
| 2011 |
Katrin Wengenroth |
Regulatory Challenges Due to Globalisation of Drug Development and Manufacture Focusing on the Quality of Medicinal Products *** |
|
|
| 2011 |
Dr. Christian Wrehlke |
Development of a database concept for tracking and maintaining regional/country specific Product Information (PI) and PI requirements |
|
|
| 2011 |
Frauke Zeller, (geb. Tuchalski) |
Development of a new medicinal product containing a NCE intended for global marketing taking national regulations and requirements in the MENA region into consideration |
|
|
| 2010 |
Sigrun Adrian |
Die Entwicklung unterschiedlicher Rechtsvorschriften und deren Überwachung im Bereich der Sicherheit von Arzneimitteln und Medizinprodukten in Deutschland (Pharmako- und Medizinproduktevigilanz) |
|
|
| 2010 |
Stanislaus Awrutski |
Drug Regulatory Affairs and Marketing Authorisation in the Post-Soviet countries. Focus: Russia, the Ukraine and Belarus |
|
|